Nevertheless, our data acquired through the use of the class I-specific HDAC inhibitor mocetinostat as well as the broad-spectrum HDAC inhibitors CUDC-101 and pracinostat negatively impacting DSB repair efficiency in HPV-negative HNSCC cells would correlate with this previous evidence. Here, HDAC9 is linked to head and neck squamous cell carcinoma.